Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 43

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 43
---

 NewcelX AG                                                                                                                                                                                                    
 NewcelX SA                                                                                                                                                                                                    
 NewcelX Ltd                                                                                                                                                                                                   
 is a stock corporation pursuant to these articles of association and to article 620 et seqq. of the Swiss Code of Obligations, formed for an indefinite duration and having its registered office in Kloten.” |

9.Election of the New Board of Directors Explanation:Pursuant to the Merger Agreement, the current members of the Board of Directors (excluding Alexander Zwyer and Olivier Samuel) must resign from their positions immediately prior to the Effective Time. A new Board of Directors, as designated by Kadimastem, shall be elected. The proposed members are: Mr. Ronen Twito:Mr.Ronen Twito, has served as Kadimastem’s Executive Chairman of the Board of Directors since December 2020 and its Chief Executive Officer since December 2024. Mr.Twito brings over two decades of executive leadership experience in the biotech and high -techsectors, across both Nasdaq and TASE listed companies. Mr.Twito also served as the Chairman of the board of Bubbles Intergroup Ltd (TASE: “BBLS”) since January 2022. From March 2019 until August 2021, he served as an Independent Director at Mer Telemanagement Solutions Ltd. (Nasdaq: “MTSL”). From November 2015 to March 2017, Mr.Ronen Twito served as Deputy Chief Executive Officer and CFO at Cellect Biotechnology Ltd. (Nasdaq: “APOP”). From May 2014 until November 2015, he served as Vice President of Finance at BioBlast Pharma Ltd. (Nasdaq: “ORPN”) (merged in later stage with Enlivex Therapeutics, Nasdaq: “ENLV”). From June 2009 to April 2014, Mr.Twito served as Deputy Chief Executive Officer and CFO at XTL Biopharmaceuticals Ltd. (Nasdaq: “XTLB”). Mr.Twito served as the Chief Executive Officer of InterCure Ltd. (subsidiary of XTL) from 2011 to 2012 (TASE: “INCR”). From November 2004 to June 2009 he served as Corporate Finance Director at Leadcom Integrated Solutions (London, AIM: “LEAD”). From January 2000 to November 2004, he served as Audit Manager at EY. Mr.Twito is a